![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Madaus, S.A. |
Information provided by: | Madaus, S.A. |
ClinicalTrials.gov Identifier: | NCT00507715 |
The purpose of this trial is to study the effect of the association levodopa/carbidopa with plantago ovata husk in Parkinson´s disease patients of recent diagnostic, that are being treated with levodopa/carbidopa.
Condition | Intervention | Phase |
Parkinson's Disease, Idiopathic |
Drug: Plantago ovata husk Other: hemicellulose crystalline |
Phase I |
Genetics Home Reference related topics: | familial paroxysmal nonkinesigenic dyskinesia Parkinson disease |
MedlinePlus related topics: | Parkinson's Disease |
ChemIDplus related topics: | Levodopa Calcium polycarbophil Psyllium Hemicellulose |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study |
Official Title: | Clinical Trial to Study the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk |
Enrollment: | 18 |
Study Start Date: | September 2006 |
Study Completion Date: | November 2006 |
Arms | Assigned Interventions |
1: Experimental
Plantago ovata husk
|
Drug: Plantago ovata husk
5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
|
2: Placebo Comparator
hemicellulose crystalline
|
Other: hemicellulose crystalline
5g effervescent powder t.id. during 14 days
|
Although the treatment with l-dopa is the election treatment for Parkinson´s disease, a high number of patients develop motor complications, including, fluctuations and dyscinesia after some years of treatment.
The origin of the fluctuations is not well established, but it could be attributed, al least partially, a pharmacokinetics factors. So that, it could improve the answer and reduce the adverse reaction if we reach more stable levels of L-dopa in the circulation. The first experimental studies in animals showed that Plantago ovata husk has an influence in the pharmacokinetics parameters of L-dopa, obtaining more stable levels.
Ages Eligible for Study: | 60 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Spain, León | |||||
Hospital de León | |||||
Leon, León, Spain, 24071 |
Madaus, S.A. |
Study Chair: | Sierra Matilde, Ph, phD | Departamento de Ciencias Biomédicas de la Facultad de Veterinaria de la Universidad de León, León (Spain) |
Principal Investigator: | Carriedo Demetrio, MD | Hospital de León, León (Spain) |
Study ID Numbers: | PLAN-EC-LDOPA-FI, EudraCT number:2006-000491-33 |
First Received: | July 25, 2007 |
Last Updated: | July 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00507715 |
Health Authority: | Spain: Spanish Agency of Medicines |
|
|
|
|
![]() |